Annovis Bio is starting a public offering to sell 19 million shares and raise about $21 million.

ANVS · Annovis Bio, Inc.

The AI's read

The cash can help keep Buntanetap studies moving and cover company costs. A director is also participating on the same terms as other investors. But the offering adds many potential shares. If investors use the warrants, each current owner's fraction of the company gets smaller. That share increase outweighs the funding benefit.